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ABSTRACT
Mer and Flt3 receptor tyrosine kinases have been implicated as therapeutic 
targets in acute myeloid leukemia (AML). In this manuscript we describe UNC1666, 
a novel ATP-competitive small molecule tyrosine kinase inhibitor, which potently 
diminishes Mer and Flt3 phosphorylation in AML. Treatment with UNC1666 mediated 
biochemical and functional effects in AML cell lines expressing Mer or Flt3 internal 
tandem duplication (ITD), including decreased phosphorylation of Mer, Flt3 and 
downstream effectors Stat, Akt and Erk, induction of apoptosis in up to 98% of cells, 
and reduction of colony formation by greater than 90%, compared to treatment with 
vehicle. These effects were dose-dependent, with inhibition of downstream signaling 
and functional effects correlating with the degree of Mer or Flt3 kinase inhibition. 
Treatment of primary AML patient samples expressing Mer and/or Flt3-ITD with 
UNC1666 also inhibited Mer and Flt3 intracellular signaling, induced apoptosis, and 
inhibited colony formation. In summary, UNC1666 is a novel potent small molecule 
tyrosine kinase inhibitor that decreases oncogenic signaling and myeloblast survival, 
thereby validating dual Mer/Flt3 inhibition as an attractive treatment strategy for AML.
INTRODUCTION
Though the treatment of acute myeloid leukemia 
(AML) has significantly improved over the past 30 years, 
average five-year survival rates are still less than 60% 
for pediatric patients and are progressively worse for 
older adult and elderly patients [1, 2]. The high-intensity 
chemotherapy needed to induce remission in AML is often 
prohibitive in elderly patients due to excessive mortality 
[3, 4], and is known to cause concerning long-term toxic 
side effects, including growth abnormalities, cardiac 
dysfunction, neurocognitive deficits, and gonadal failure 
in pediatric patients [5–7]. Novel therapies that effectively 
achieve cancer cell killing with minimal toxicity to normal 
cells are urgently needed to improve both patient outcomes 
and long-term quality of life.
The Mer receptor tyrosine kinase is abnormally 
expressed on 80–100% of AML patient samples, whereas 
little or no Mer is expressed in normal bone marrow 
precursor cells [8, 9]. Mer activation in AML cell lines 
leads to pro-survival signaling, including phosphorylation 
of Erk1/2, Akt and Stat6. Inhibition of Mer in AML 
via RNA interference led to a significant increase in 
myeloblast apoptosis, decreased colony formation in 
methylcellulose, and prolonged leukemia-free survival 
in a murine xenograft model [8]. These findings led us 
to determine that aberrant Mer expression (rather than 
activating mutation in the kinase domain) provides a 
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survival advantage in leukemia. Taken together, these 
data suggest that Mer kinase inhibition may selectively 
target leukemia cells, while sparing normal bone marrow 
progenitors.
Internal tandem duplication (ITD) mutations 
of the FMS-like tyrosine kinase 3 (Flt3) receptor, 
found in ~20–30% of adult AML patient samples and 
~15% of pediatric AML samples, is associated with 
poor prognosis in both patient populations [10–15]. 
Specifically, a high ratio of the FLT3-ITD mutant allele 
relative to the wild type allele (> 0.4) has been associated 
with a markedly poor progression-free survival [16]. 
Constitutive activation of Flt3 through the ITD mutation 
leads to downstream activation of pro-survival signaling 
pathways including Stat5, Akt and Erk1/2 [17, 18]. 
Given that Flt3 tyrosine kinase inhibitors (TKIs) have 
been effective in preclinical models of AML, Flt3 
inhibition is currently being tested in patients with Flt3-
ITD mutations. Unfortunately, resistance to Flt3 targeted 
TKIs has been reported, including selection for novel 
point mutations [19, 20]. Interestingly, different Flt3 
inhibitors do not appear to have overlapping resistance 
mutation profiles [21], such that mutations resulting in 
resistance to one inhibitor may not confer resistance to 
another. Furthermore, adverse side effects have been 
reported in patients treated with existing Flt-3 inhibitors, 
including the recent restrictions on clinical use of 
ponatinib due to higher than expected rates of arterial 
thrombosis [22]. Issues with resistance and adverse 
toxicities demonstrate the need to develop new, more 
effective therapeutic agents.
Given the high prevalence of expression of both Mer 
and Flt3 and the data indicating their oncogenic roles in 
AML, targeting them together is an attractive therapeutic 
strategy, and could potentially result in better outcomes 
in high-risk patients, reduced need for chemotherapy in 
low-risk patients, or a therapeutic option for those who 
cannot tolerate high-intensity chemotherapy. We have 
developed UNC1666, a novel Mer and Flt3 targeted 
small molecule tyrosine kinase inhibitor with therapeutic 
potential in AML. In this publication, we show that this 
ATP-binding site competitive small molecule potently 
and selectively inhibits Mer and Flt3 kinase activation 
and downstream signal transduction resulting in growth 
inhibition and apoptosis of AML cell lines and primary 
patient myeloblasts.
RESULTS
UNC1666, a novel dual specific Mer and Flt3 
tyrosine kinase inhibitor
We previously reported UNC1062 [23], a selective 
ATP-competitive type I inhibitor of Mer. However, its low 
solubility and poor in vivo pharmacokinetic properties 
made UNC1062 unsuitable for in vivo studies. To 
develop further Mer inhibitors, a new pyrrolopyrimidine 
scaffold with better solubility was introduced using 
a structure-based design approach [24]. UNC1666, a 
pyrrolopyrimidine analogue with a structure similar to 
UNC1062, is also an ATP-competitive type I inhibitor 
(Figure 1A). Analysis of the inhibition constant (Ki) 
proved this compound to be more potent and selective 
for Mer (MCE IC50 0.55 nM; Ki 0.16 nM) compared to 
previously described Mer inhibitors [23, 25]. Additionally, 
UNC1666 inhibits Flt3 (MCE IC50 0.69 nM; Ki 0.67 nM) 
equipotently in enzymatic MCE assays. A comprehensive 
protein kinase profiling panel provided by Carna 
Biosciences was used to assess off-target kinase inhibition 
mediated by UNC1666 at a concentration of 46 nM, more 
than 50-fold higher than its MCE IC50 values against Mer 
and Flt3 (Supplemental Table 2). Only the Trk proteins 
were inhibited greater than 95% in response to treatment 
with UNC1666. Additional MCE assays were performed 
to determine inhibition of TrkA (as a surrogate for the 
Trk family kinases) and revealed similar potency (MCE 
IC50 0.57 nM) (Supplemental Table 2). Furthermore, we 
analyzed the effect of UNC1666 on both Tyro-3 and Axl 
(members of the TAM receptor tyrosine kinase family 
along with Mer), which demonstrated enzymatic MCE 
IC50 values of 29 nM and 37 nM, respectively.
The small molecule UNC1653 (Figure 1B) has a 
pyrazolopyrimidine scaffold similar to UNC1062. One 
of the hinge binding hydrogen bonds was disrupted by 
introducing a methyl group, which dramatically reduced 
Mer and Flt3 activity. In these studies, we used UNC1653 
as a negative control TKI given that it has weak inhibition 
of both Mer (MCE IC50 560 nM) and Flt3 (MCE IC50 
220 nM) relative to UNC1666.
UNC1666 reduces Mer and Flt3-mediated  
anti-apoptotic and pro-survival signaling
We have previously described survival and 
proliferation signaling resulting from Mer tyrosine kinase 
activity in AML, including increased activation of Erk1/2, 
Akt and Stat6 [8]. Similarly, others have demonstrated that 
Erk1/2, Akt and Stat5 are critical downstream survival and 
proliferation signals in AML cells with Flt3-ITD mutations 
[17, 18]. Given the degree of overlap in Mer and Flt3-
ITD signaling pathways, we first determined whether 
UNC1666 could inhibit each kinase independently in 
AML cell lines. The Kasumi-1 and NOMO-1 cell lines 
express Mer but do not have activating Flt3 mutations. 
We previously showed that short hairpin RNA-mediated 
inhibition of Mer expression in the Kasumi-1 and NOMO-
1 cell lines increased stress-induced apoptosis and 
decreased colony formation [8]. Conversely, we analyzed 
MV4;11 (homozygous for the Flt3-ITD, high allelic ratio 
or “Flt3-ITDhighAR”) and MOLM-13 (heterogygous for 
the Flt3-ITD, low allelic ratio or “Flt3-ITDlowAR”), which 
express little (“dim”) and no Mer respectively, and have 
been used extensively as models of leukemia with Flt3-
ITD mutations.
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Using these cell lines, we confirmed that short-
term treatment with UNC1666 reduced Mer and 
Flt3 phosphorylation in a dose dependent manner, 
compared to vehicle alone (DMSO) or negative control 
UNC1653 (Figure 2A & 2B). UNC1666 decreased Flt3 
phosphorylation more potently in Flt3-ITD cell lines, 
as compared to Flt3 wild-type cell lines (Figure 2B and 
data not shown). Mer and Flt3 phospho-protein levels 
were reduced by approximately half at concentrations of 
100 nM and 50 nM, respectively.
To investigate whether inhibition of other kinases 
might contribute to effects mediated by UNC1666, we also 
assessed expression of the Trk kinases as well as Tyro-3 and 
Axl. The cells lines used for these studies express very little 
or no Tyro-3, Axl or Trk protein (Supplemental Figure 1).
We then evaluated downstream Erk, Akt and Stat 
signaling after a two hour treatment with UNC1666. 
There was a consistent dose-dependent abrogation of 
Erk1/2, Akt and Stat6 phosphorylation in Mer expressing 
cell lines treated with UNC1666 compared to vehicle or 
UNC1653 (Figure 2C and Supplemental Figure 2). The 
decreased phosphorylation of these molecules correlated 
with the decrease in Mer phosphorylation (Figures 2A 
and 2C); diminished phosphorylation was noted at 50 nM, a 
moderate decrease at 100 nM, and more complete inhibition 
at 300 nM. Additionally, phosphorylation of Erk1/2, Akt 
and Stat5 was markedly diminished in the Flt3-ITD cell 
lines after treatment with UNC1666 compared to vehicle or 
UNC1653 (Figure 2D and Supplemental Figure 2). Again, 
decreased phosphorylation of these pro-survival signaling 
molecules in Flt3-ITD cell lines correlated with a decrease 
in Flt3 phosphorylation (Figures 2B and 2D); near complete 
ablation of phosphorylation was observed at 50 nM.
UNC1666 induces apoptosis in AML cell lines
To analyze the functional effects mediated by 
UNC1666, AML cell lines were treated with UNC1666, 
Figure 1: UNC1666 is a novel inhibitor of Mer and Flt3 tyrosine kinases. (A) Chemical structure of UNC1666, with inhibition 
constant (Ki) of 0.16 nM for Mer (enzymatic IC50: 0.55 nM) and 0.67 nM for Flt3 (enzymatic IC50: 0.69 nM). (B) Chemical structure 
of UNC1653, which lacks significant activity against Mer (enzymatic IC50: 560 nM) and Flt3 (enzymatic IC50: 220 nM) and is used 
as a negative control in these studies. (C) Whole cell lysates from AML cell lines with known Flt3 mutation status were analyzed by 
immunoblot and demonstrate presence or absence of the Mer tyrosine kinase (above) and the Flt3 tyrosine kinase (middle). Actin is shown 
as an indicator of total protein (below).
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vehicle or negative control UNC1653 for 72 hours and 
cells were analyzed by flow cytometry after staining 
with YO-PRO-1 iodide and propidium iodide dyes, 
compounds that are taken up by early apoptotic or late 
apoptotic/dead cells, respectively (Figure 3A). Treatment 
of Mer-positive cell lines with UNC1666 resulted 
in a dose-dependent induction of apoptosis relative 
to vehicle-treated cells (Figure 3B & Supplemental 
Figure 3A). Mer-expressing cell lines exhibited a 
significant induction of apoptosis in 50–67% of cells 
at 100 nM and an even more dramatic induction of 
apoptosis in 68–76% of cells at 300 nM. For example, in 
the Kasumi-1 cell line 30 ± 7% of cells were apoptotic 
or dead after 72 hour treatment with vehicle compared 
to 76 ± 8% after treatment with 300 nM UNC1666 (p < 
0.001). Importantly, apoptosis was induced at the same 
concentrations of UNC1666 required for inhibition of 
Mer (Figures 2A and 3B). In Flt3-ITD cell lines, treatment 
with UNC1666 resulted in an even more dramatic 
induction of apoptosis (Figure 3B & Supplemental 
Figure 2: UNC1666 reduces Mer and Flt3-mediated signaling through downstream anti-apoptotic and pro-survival 
pathways. (A) Mer was immunoprecipitated from AML cell lysates and phosphorylated (p-Mer) and total Mer (~180 kDa) levels were 
assessed by immunoblot analysis. This representative blot of the Kasumi-1 cell line demonstrates decreased Mer phosphorylation after 
treatment with increasing doses of UNC1666. (B) Flt3 was immunoprecipitated from AML cell lysates and phosphorylated (p-Flt3) and total 
Flt3 (130/160 kDa) levels were assessed by immunoblot analysis. This representative blot of the MV4;11 cell line demonstrates decreased 
Flt3 phosphorylation after treatment with increasing doses of UNC1666. (C) Inhibition of downstream signaling after administration 
of UNC1666 in a Mer expressing AML cell lines that does not express a Flt3-ITD mutation (Kasumi-1) compared with equivalent 
concentrations of vehicle (DMSO) or inactive control TKI UNC1653. Actin is shown as an indicator of total protein. (D) Downstream 
signaling after administration of UNC1666 in a Flt3-ITD AML cell line that does not express Mer (MV4;11). Representative blots from at 
least 3 independent experiments are shown. nM = nanomolar
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Figure 3A). At 50 nM, 54–67% of Flt3-ITD cells were 
apoptotic or dead, increasing up to 90–98% at 300 nM. 
More specifically, the MV4;11 cell line demonstrated 
13 ± 3% apoptosis after treatment with vehicle versus 
90 ± 1% after treatment with 300 nM UNC1666, and the 
MOLM-13 cell line demonstrated respective means of 8 
± 1% and 98 ± 2% (both p < 0.001). Again, induction of 
apoptosis correlated with inhibition of Flt3 (Figures 2B 
and 3B). Treatment with negative control UNC1653 did 
not induce apoptosis in Mer-expressing or Flt3-ITD cell 
lines (Figure 3B). Induction of apoptosis was confirmed 
by immunoblot demonstrating increased cleavage of 
PARP and Caspase-3 after treatment with UNC1666 
(Figure 3C). Cell cycle analysis indicated a trend towards 
Figure 3: UNC1666 induces apoptosis in myeloblasts expressing Mer or Flt3-ITD. Merpos or Flt3-ITD AML cell lines were 
treated with UNC1666, vehicle (DMSO), or inactive control TKI UNC1653 for 72 hours and then analyzed by flow cytometry after staining 
with YO-PRO-1 iodide and propidium iodide to identify apoptotic and dead cells. (A) Representative flow cytometry profiles of Kasumi-1 
cells are shown. The percentages of live (lower left quadrant), early apoptotic (lower right quadrant), and late apoptotic/dead cells (upper 
quadrants) are shown. (B) Graphic representation of flow cytometric analyses of apoptotic/dead cells. Mean values and standard errors 
were derived from at least 3 independent experiments. *p < 0.05, ***p < 0.001, NS = not significant. (C) Cells were treated as indicated 
for 72 hours, whole cell lysates were prepared and the indicated apoptotic proteins were assessed by immunoblot analysis. Actin is shown 
as a loading control.
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accumulation of cells in G2M phase with 4N DNA 
content and this was significant at the 300 nM dose of 
UNC1666 (Figure 4 and Supplemental Figure 3B).
UNC1666 affects growth & proliferation of AML 
cells even after treatment
Malignant cells have previously demonstrated 
rebound growth after removal of TKIs in some clinical 
trials [26]. To evaluate the sustained effect of UNC1666 
on cell growth and survival after removal of treatment, 
AML cell lines were cultured with UNC1666 or vehicle 
for 72 hours, then cells were washed and replated at 
1.5 × 104 viable cells/ml in normal culture conditions 
(Day 0). Cells were counted after six days of culture 
(Day 6) to assess rebound growth (Figure 5A). Although 
30–75% of cells remain viable after treatment with 
50 nM UNC1666 compared to vehicle (Figure 3B and 
Supplemental Figure 3A), these cells demonstrate a 
significant decrease in their ability to proliferate even 
after UNC1666 removal (Figure 5B and Supplemental 
Figure 3C). Samples treated with higher concentrations 
of UNC1666 had even more striking cell proliferation 
defects, leading to only a minimal number of viable cells 
at Day 6 in all four cell lines. The Kasumi-1 cell line 
treated with vehicle demonstrated an average 14-fold 
increase in viable cell number (from 1.5 × 104 to 2.0 × 105 
viable cells/ml) over six days, whereas those treated with 
100 nM UNC1666 only increased 2.5-fold (to 0.3 × 105 
cells/ml) (p < 0.001). The MV4;11 cell line treated with 
vehicle demonstrated an average 67-fold increase (from 
1.5 × 104 to 10 × 105 viable cells/ml) whereas cells 
treated with 50 nM UNC1666 only increased 13-fold 
(to 2.0 × 105 viable cells/ml) (p < 0.001).
UNC1666 decreases colony formation  
in AML cell lines
To assess the effect of UNC1666 in a longer-term 
assay which might more closely approximate the three-
dimensional environment encountered in vivo, AML cell 
lines were plated in equal number in soft agar and treated 
with UNC1666, negative control UNC1653, or vehicle in 
the overlaying medium. Vehicle treatment was assessed in 
duplicate and data from samples treated with UNC1666 
or UNC1653 were normalized to the mean vehicle colony 
number for each experiment. Treatment with UNC1666 
significantly decreased colony formation compared to 
cells treated with medium containing vehicle or UNC1653 
(Figure 5C & Supplemental Figure 3D). The Kasumi-1 
and NOMO-1 cell lines demonstrated a 90 ± 6% and 
71 ± 4% reduction in colony formation, respectively, in 
response to 100 nM UNC1666, while the MV4;11 and 
MOLM-13 cells line demonstrated a 61 ± 22% and 93 
± 6% reduction in colonies, respectively, in response to 
treatment with 50 nM UNC1666 (p < 0.001).
UNC1666 inhibits downstream signaling  
in primary AML cells
Mer and wild-type Flt3 expression levels were 
assessed in blasts obtained from six patients diagnosed 
with acute myeloid leukemia using immunoblot analysis 
(Figure 6A), and FLT3-ITD alleles were detected using 
standard clinical molecular techniques (Figure 6B). 
Additional clinical information relevant to each patient 
samples is described in Figure 6B. In our ongoing 
studies, we have not identified any cell line other than 
MV4;11 (which expresses very little Mer) that jointly 
Figure 4: UNC1666 results in G2/M cell cycle arrest at higher concentrations. Mer positive or Flt3-ITD AML cell lines were 
treated with UNC1666, vehicle (DMSO), or inactive control TKI UNC1653 for 72 hours, fixed with 100% ethanol and then analyzed 
by flow cytometry after staining with propidium iodide to identify stage of cell cycle. Graphic representation of cell cycle progress in 
Kasumi-1 and MV4;11 cells using ModFit analysis are shown. The percentages of cells in G2/M (light gray), S (white), and G1 (dark gray) 
phases are shown. Mean values and standard errors were derived from at least 3 independent experiments. *p < 0.05, **p < 0.01.
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expresses Mer and a Flt3-ITD mutation (data not shown), 
however five out of six of our randomly obtained patient 
samples did co-express these molecules. All samples 
expressed Mer (consistent with our previously published 
results), but demonstrated a range of Mer expression 
levels (Figure 6A). Since sensitivity of Mer expressing 
malignant cell lines does not appear to directly correlate 
with the degree of Mer expression (data not shown) and 
Mer dependence may instead be related to autocrine ligand 
expression or some other property of the cell, we opted to 
score all patient samples that express Mer as Mer positive 
(Merpos). All samples except #123009 expressed Flt3-
ITD mutations, though #11612 and #41206 were noted 
to have a low allelic ratio. Since there is a correlation 
between high allelic ratio of the Flt3-ITD (> 0.4) and 
poor prognosis in patients [16], we accordingly denoted 
when a patient sample was of high (“Flt3-ITDhighAR”) or 
low (“Flt3-ITDlowAR”) Flt3 allelic ratio. None of the patient 
samples demonstrate detectable levels of Trk proteins 
(Supplemental Figure 4A). Sample #10510, which was 
Merpos and Flt3-ITDhighAR, was analyzed to determine 
intracellular signaling alterations after treatment with 
Figure 5: UNC1666 diminishes myeloblast rebound growth and colony formation in AML cell lines expressing Mer 
or Flt3-ITD. (A) Diagram of the replating assay. Cells were treated with UNC1666 or vehicle for 72 hours, then washed to remove 
any residual compound and equal numbers of viable cells (1.5 × 104/ml) were replated in growth medium on Day 0. On Day 6 after 
replating, the number of viable cells was determined. (B) Graphic representation of the results of the replating assay in Mer or Flt3-ITD 
expressing cell lines demonstrating decreased rebound growth after treatment with UNC1666. Mean values and standard errors were 
derived from at least 3 independent experiments. (C) Colony-formation assays were performed using Mer or Flt3-ITD expressing AML 
cell lines. Cells were grown in soft agar with the indicated treatments. Graphic representation of reduced colony number after treatment 
with UNC1666, compared to vehicle or negative control TKI UNC1653. Mean values and standard errors were derived from at least 3 
independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, NS = not significant.
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Figure 6: UNC1666 inhibits Mer and Flt3 dependent signaling in AML patient samples. (A) Immunoblot analysis of Mer 
and Flt3 expression in lysates prepared from AML patient samples. (B) Flt3 mutation status of patient samples determined by molecular 
profiling. (C, D) Dose-dependent inhibition of Mer and Flt3 phosphorylation in response to treatment with UNC1666. AML blasts from 
patient sample #10510 (Mer positive, Flt3-ITD high allelic ratio) were treated with UNC1666 or vehicle for two hours. (C) Mer and Flt3 
were immunoprecipitated from cell lysates and phosphorylated Mer (p-Mer), total Mer (~180 kDa), phosphorylated Flt3 (p-Flt3) and total 
Flt3 (130/160 kDa) were detected by immunoblot. (D) Phosphorylation of downstream signaling molecules was assessed by immunoblot 
after treatment with UNC1666 or vehicle.
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UNC1666. Mer and Flt3 were immunoprecipitated from 
whole cell lysates and immunoblot analysis confirmed 
inhibition of both kinases in response to UNC1666 
(Figure 6C). Phosphorylation of both Mer and Flt3 
was inhibited by greater that 50% after treatment with 
UNC1666 at concentrations as low as 50 nM, though 
it is notable that UNC1666 appears to decrease Flt3 
phosphorylation at a lower dose compared to its effect 
on Mer, similar to what was observed in cell lines. 
Immunoblot analysis of Erk1/2, Akt and Stat5 phospho-
proteins demonstrated marked decreases in response to 
UNC1666 treatment (Figure 6D), which correlated the 
decrease in Mer and Flt3 phosphorylation status.
UNC1666 induces apoptosis in primary  
AML patient samples
To replicate the conditions utilized with AML 
cell lines, patient samples were treated with UNC1666 
or vehicle and apoptosis was determined using flow 
cytometry as described above. Patient samples were 
co-cultured with HS27 stromal cells, which provide 
essential factors to support myeloid cells and allowed us 
to assess response to UNC1666. Under the stromal cell 
enhanced growth conditions, treatment with UNC1666 
was sufficient to induce apoptosis in all patient samples, 
thereby demonstrating efficacy on AML blasts with a 
wide range of Mer expression levels or Flt3-ITD status 
(Figure 7A & Supplemental Figure 4B). Induction of 
apoptosis in response to UNC1666 was independent 
of position in the cell cycle, though at high doses may 
correlate with accumulation in G2/M phase as previously 
noted in AML cell lines (Supplemental Figure 4C).
UNC1666 decreases colony formation in 
methylcellulose in primary AML patient samples
To determine the effects of UNC1666 on colony-
forming potential, AML patient samples were cultured 
in methylcellulose with the compound or vehicle for 
10 days and colonies were counted in a blinded manner. 
Patient samples grew variably under these conditions, 
so experimental data are reported as colony number rela-
tive to vehicle-treated cultures to facilitate comparison 
between samples. UNC1666 treatment dramatically 
decreased colony numbers in all patient samples and 
mediated near complete abrogation of colony formation 
at concentrations as low as 50 nM in all but one sample 
(Figure 7B & Supplemental Figure 4D).
UNC1666 provides a broad therapeutic dosing 
window in normal hematopoietic precursors
A similar evaluation was performed to determine 
the effects of treatment with UNC1666 or vehicle control 
on hematopoietic precursors in methylcellulose cultures 
of normal umbilical cord blood samples. In these studies 
there was no significant reduction in colony number at 
doses up to 500 nM UNC1666 (n = 3, Figure 7C). Upon 
treatment with 1 μM UNC1666, there is a trend towards 
decreased colony formation, and this becomes statistically 
significant at a dose of 10 μM.
DISCUSSION
The unacceptable cure rate and toxic consequences 
of intensive chemotherapy support the development of 
novel targeted therapies to improve long-term clinical 
outcomes in AML. Our previous work demonstrated 
the upregulation of the Mer tyrosine kinase in nearly 
all adult and pediatric patient samples collected at 
diagnosis or relapse. In contrast, normal bone marrow 
progenitors express very little Mer [8, 9]. We previously 
found that inhibition of Mer using RNA interference 
induced apoptosis and decreased proliferation in vitro and 
prolonged survival in vivo in xenograft models. These 
results indicated a potential therapeutic role for Mer 
kinase inhibition. In an effort to discover Mer-selective 
inhibitors, we generated UNC1666, which also inhibits 
Flt3 at nearly equal potency in enzymatic assays. The 
sequence identity between the binding pockets of Mer and 
Flt3 (defined as all residues whose side chains are within 
4.5 Å distance from UNC1666) is > 90% (one differing 
residue). In contrast, the sequence identity for the full 
Mer kinase domain compared to the full kinase domain 
of Flt3 is ~30%. UNC1666 exhibits selectivity for Mer 
and Flt3 over other kinases tested, with greater than 50-
fold selectivity over closely related and structurally similar 
kinases Tyro-3 and Axl, co-members with Mer in the TAM 
family.
We have found that Mer and Flt3-ITD can be co-
expressed on AML patient samples, though a larger cohort 
of patient samples is needed to determine the frequency 
of dual Mer expression and Flt3-ITD mutation. Currently, 
little is known about the physical association of Mer and 
Flt3 receptors on leukemic blasts. Though studies to assess 
the physical association of Mer and Flt3 have not been 
reported, co-localization of Flt-3 and Axl, a member of the 
TAM kinase family along with Mer has been demonstrated 
[27]. Based on the structural homology of Mer and Axl, it 
is possible that Mer and Flt-3 might also co-localize and 
perhaps directly associate.
Given that Flt3-ITD is a known oncogenic target in 
AML and Mer is also known to play essential oncogenic 
roles in AML cells, combined inhibition of Mer and Flt3 is 
likely to be an effective strategy with broad applicability. 
Thus, we tested the efficacy of our dual Mer/Flt3 TKI in 
AML cell lines and patient samples. The MCE enzymatic 
assay data indicate that UNC1666 inhibits Mer and 
Flt3 with nearly equal potency. However, in cell-based 
assays, UNC1666 was more effective at reducing Flt3 
phosphorylation compared to Mer phosphorylation. 
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Figure 7: UNC1666 induces apoptosis and decreases colony formation in AML patient samples. (A) Graphic representation 
of apoptosis and cell death in AML patient samples after treatment with UNC1666 or vehicle for 72 hours. Apoptotic and dead cells were 
determined by flow cytometry after staining with YO-PRO-1 iodide and propidium iodide. Values derived from each sample are shown. 
(B) Colony-forming assays were performed in methylcellulose with the indicated treatments. Graphic representation of reduced colony 
number after treatment with UNC1666, compared to vehicle. Mean values and standard errors derived from triplicate samples are shown. 
(C) Graphic representation of the effect of UNC1666 on normal cord blood colony forming potential. Mean values and standard errors were 
derived from 3 independent experiments. **p < 0.01, NS = not significant.
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Inhibition of Mer and Flt3 phosphorylation in cell based 
assays correlated with functional effects mediated by 
UNC1666 in cell lines expressing Mer or Flt3-ITD.
Previously, we demonstrated signaling downstream 
of Mer through the pro-survival and anti-apoptotic 
Erk1/2, Akt and Stat6 pathways in AML. Other groups 
have shown similar downstream effectors of Flt3-ITD 
including Erk1/2, Akt and Stat5. Though there are have 
been additional effectors known downstream of both 
Mer and Flt3 in various cell types, we chose to analyze 
these molecules which function to promote cancer cell 
growth and prevent apoptosis and have well-characterized 
roles in leukemogenesis. In addition, other groups have 
noted heterogeneity in the phosphorylation status of all 
three of these molecules (in both Mer and/or Flt3-ITD 
dependent cell lines) depending on the cell line, tumor 
type, assay, and/or in vitro therapeutic intervention. Given 
the heterogeneity of downstream effector phosphorylation 
status in a given AML cell line or patient sample, blockade 
of both Mer and Flt3 signaling may affect independent 
downstream pathways and/or may function redundantly to 
more effectively inhibit shared pathways. Targeting these 
mutual pathways had a profound functional effect in AML 
patient samples that co-expressed Mer and Flt3, including 
decreased ability to evade apoptosis and decreased colony 
formation. Each of these effects occurred at concentrations 
between 5–100 nM, and correlated well with inhibition 
of Mer and Flt3 phosphorylation in cell-based assays. 
The observed correlations between inhibition of Mer or 
Flt3 and functional anti-leukemia effects mediated by 
UNC1666 in AML cells suggest that these effects are a 
result of on-target inhibition of Mer and Flt3, rather than 
non-specific inhibition of other kinases.
The studies presented here extend the action of 
UNC1666 to primary patient AML blasts. Interestingly, 
the anti-proliferative effects in patient samples were 
even more dramatic than in cell lines with near complete 
induction of apoptosis and growth inhibition at 50 nM. 
The patient sample conditions (co-culture with stromal 
cells) suggest that Mer inhibition is likely to be effective 
even in the bone marrow microenvironment. The bone 
marrow niche provides a potential rich source of paracrine 
Gas6 [28, 29], a Mer ligand, and the ability of Mer 
inhibitors to abrogate this niche survival pathway may 
be crucial in improving clinical outcomes in patients. 
Interestingly, in cell lines treatment with UNC1666 did 
not have a significant effect on the cell cycle unless high 
concentrations (300 nM) were used. This effect was also 
observed in a subset of patient samples, although less 
consistently. This suggests that blast survival is more 
profoundly affected than proliferation, and that inhibition 
of Mer or Flt3 decreases survival at any stage of the cell 
cycle. Additionally, although patient-derived myeloblasts 
are sensitive to UNC1666 in methylcellulose cultures at 
concentrations as low as 5–50 nM, it is important to note 
that UNC1666 did not affect the colony forming poten-
tial of hematopoietic progenitors in normal cord blood 
cultures, even at doses as high as 1 μM. These data suggest 
the possibility of minimal bone marrow progenitor toxicity 
in response to treatment with a dual Mer/Flt3 inhibitor 
such as UNC1666, even at doses considerably higher 
than are necessary to decrease receptor phosphorylation 
and inhibit oncogenic phenotypes and indicate a wide 
therapeutic window with minimal hematopoietic side 
effects at doses up to 1 μM. Hematopoietic progenitors 
have previously been described as Mer negative [8, 
9]. Therefore, a Mer targeted inhibitor acting in the 
bone marrow microenvironment is likely to target only 
Mer-expressing leukemia cells.
Initially, UNC1666 was designed to have 
greater solubility to improve in vivo bioavailability 
and pharmacokinetics as compared to earlier Mer 
inhibitors [23, 30]. Unfortunately, following intravenous 
administration in a murine model, UNC1666 demonstrated 
a terminal elimination half-life of 0.23 hour, and follow-
ing oral administration of UNC1666, the absolute oral 
bioavailability was low (8%). Due to these observations, 
we have continued optimization to seek compounds 
that inhibit Mer and Flt3 with extended plasma half-
life and improved bioavailability. However, the studies 
presented here provide an important proof-of-principal 
demonstrating that inhibition of Mer or Flt3 has a 
profound effect on the survival and continued proliferation 
of myeloblasts and suggest that inhibitors targeting both 
of these kinases may be particularly effective and/or have 
broad-spectrum clinical application in patients with AML. 
Given that our in vitro work with primary patient samples 
demonstrated a dramatic effect at concentrations well 
within the range of what is clinically achievable using 
orally bioavailable TKIs, we anticipate that improved 
analogues will have similar results both in vitro and 
in vivo.
Because UNC1666 has poor in vivo bioavailability 
and a short half-life (data not shown), it was not possible 
to assess the toxicity profile associated with dual Mer/
Flt3 inhibition in mice. As previously described, Flt3 
inhibitors such as AC-220 are known have side effects 
including myelosuppression, though this is variable and 
is not present with some newer generation Flt3 inhibitors 
[31] due to improved specificity and decreased off-target 
effects. We would anticipate that UNC1666 would have 
a side effect profile similar to these newer generation 
inhibitors given that they have high specificity for Flt3. 
Additionally, Mer is not expressed in normal marrow 
progenitors [8, 9]. Previous analysis by our group on 
bone marrow progenitors in Mer knockout mice show 
there is a slight decrease in granulocyte-macrophage 
populations compared to wild-type mice, which is of 
questionable clinical significance [9]. Other progenitor or 
stem cell populations were not affected in these studies. In 
pedigrees describing humans with complete Mer protein 
loss-of-function, the identified cases lived to adulthood, 
though they develop clinical conditions such as retinitis 
pigmentosa, which is thought to be mainly a result of 
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the long-term defects in Mer-dependent clearance of 
apoptotic cells in the retina. In rat models of retinitis 
pigmentosa with Mer gene deletion, when the Mer gene 
was exogenously expressed in the retina, the disease 
phenotype was corrected [32], indicating that the condition 
was not permanent. These observations suggest that short-
term use of a Mer inhibitor for cancer therapy is unlikely 
to have an effect as severe as the phenotype observed in 
patients with Mer loss-of-function mutations and that any 
observed effects will be reversible. These observations 
suggest that short-term use of a Mer inhibitor for cancer 
therapy is unlikely to have an effect as severe as the 
phenotype observed in patients with Mer loss-of-function 
mutations and that any observed effects will be reversible. 
While our studies using cord blood progenitors and the 
phenotypes associated with loss of Mer function suggest 
that Mer inhibition will be well-tolerated, there are no Mer 
selective inhibitors that have been tested in vertebrates and 
thus toxicity profiles have not been established.
Despite our finding that the majority of Mer-
expressing cell lines have at least some degree of 
response to treatment with UNC1666 in apoptosis and 
colony formation assays, the level of Mer protein does not 
correlate with sensitivity to UNC1666. This observation 
has recently led to initiation of studies to investigate the 
characteristics of AML cells that might predict sensitivity 
to Mer inhibition. Based on previous studies indicating 
a prognostic role for Gas6 in AML, we hypothesize that 
paracrine or autocrine expression of Gas6 (or other Mer 
ligands) by the leukemia cell itself or by the supportive 
marrow stroma [29, 33], could serve as a clinical 
biomarker, however further investigation is needed.
In summary, Mer and Flt3 inhibition was effective at 
profoundly diminishing survival of AML blasts in both cell 
lines and primary patient samples. UNC1666 decreased 
Mer and Flt3 phosphorylation/activation and abrogated 
downstream signaling through the Stat, Akt and Erk 
pathways. The dose required for these signaling effects 
correlated well with induction of apoptosis and decreased 
colony formation. Prolonged effects were even noted on 
seemingly viable cell populations in replating assays, a 
promising indication for future in vivo experimentation 
with more bioavailable compounds that share UNC1666’s 
improved potency. These data also suggest a potential role 
for dual Mer/Flt3 inhibition in the treatment of human 
AML, where there is a true need for targeted agents to 
treat patients more effectively.
Interestingly, several additional cancers are known 
to aberrantly express Mer, including acute lymphoblastic 
leukemia and melanoma, and inhibition of Mer in these 
cancers has demonstrated significant effects on malignant 
cell survival and apoptosis [9, 34]. These malignancies 
are also likely to benefit from the development of 
newer generation Mer inhibitors with improved in vivo 
bioavailability for use in the treatment of human disease, 
though it is not clear if these cancers would equally benefit 
from the dual Mer/Flt3 inhibition. The data presented here 
are likely to lead to a multitude of additional studies of 
our Mer/Flt3 inhibitors exemplified here by UNC1666, 
including evaluation of potential synergistic combination 
therapy, assessment in murine xenograft mice using 
patient derived xenografts, and ultimately to phase I 
clinical trials. The hypothesis that Mer is providing 
the neoplastic cell with a survival advantage and the 
observation that Mer inhibition sensitizes cancer cells to 
chemotherapy [9] suggest that combination with cytotoxic 
therapy may be particularly efficacious, potentially 
allowing for chemotherapy dose-reduction. In AML, the 
dual Mer/Flt3 activity of this series of compounds should 
provide additional efficacy relative to inhibition of either 
kinase alone. Ultimately, the use of similar inhibitors 
is anticipated to improve the treatment of AML, with 
potential to decrease relapse rates and as a treatment 
option for patients who are not able to tolerate the toxicity 
of current standard chemotherapeutics.
METHODS
Compound development and kinase assays
UNC1666 and UNC1653 (a non-active analog) 
were prepared as previously described [24, 30]. Kinase 
inhibition profiling was performed by Carna Biosciences 
to assess for off-target inhibition mediated by UNC1666. 
Inhibition constants of Mer, Flt3, Tyro3 and Axl kinase 
activity by UNC1666 was determined at the Km for ATP 
using a microfluidic capillary electrophoresis (MCE) assay 
[35–37] in which phosphorylated and unphosphorylated 
substrate peptides were separated and analyzed using a 
LabChip EZ Reader [23, 30]. See Supplemental Methods 
for additional information. For in vitro studies, compounds 
were dissolved in dimethyl sulfoxide (DMSO; Sigma). 
DMSO equivalent to the 300 nM UNC1666 treatment was 
used as a vehicle control.
Patient samples and cell culture
Cell lines MV4;11, NOMO-1, KG-1a, NB-4, 
and HEL were obtained from the German Collection of 
Microorganisms and Cell Culture (DSMZ); Kasumi-1 
and U937 were obtained from the American Type Culture 
Collection (ATCC); MOLM-13 was a gift from Robert 
Arceci (Johns Hopkins); HS-27 was a gift from Kathrin 
Bernt (University of Colorado). AML cell lines were 
maintained in RPMI medium (HyClone) supplemented 
with 10% FBS and penicillin/streptomycin (cRPMI). 
Cell line identities were confirmed using short tandem 
repeat microsatellite loci analysis. HS-27 stromal cells 
were maintained in DMEM with 10% FBS and penicillin/
streptomycin prior to co-culture. De-identified cord blood 
samples and primary patient myeloblasts apheresed from 
peripheral blood were obtained from the University of 
Colorado after written informed consent in accordance 
with the Declaration of Helsinki. Experiments conformed 
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to regulatory standards as approved by the Colorado 
Multiple Institutional Review Board. AML patient samples 
were maintained as previously described [38], with HS-27 
stromal co-culture for apoptosis and cell cycle experiments.
Immunoblot analysis
Three million cells per condition were cultured in 
24-well plates and treated with UNC1666, UNC1653, or 
vehicle for two hours. Whole cell lysates were prepared 
and proteins were resolved on Tris-Glycine SDS-PAGE 
gels (Invitrogen) and transferred onto nitrocellulose 
membranes. Membranes were blocked in tris-buffered 
saline with 0.1% Tween-20 containing 5% bovine serum 
albumin (when probing for Flt3) or 5% milk (when 
probing for all other molecules). For immunoprecipitation 
assays, cells were plated and treated as above, then 
treated with pervanadate for 10 minutes prior to cell lysis 
to stabilize the phosphorylation status. With the use of 
pervandate, it was not necessary to stimulate cells with 
exogenous Mer or Flt3 ligands (other than from fetal 
bovine serum) to detect phosphorylated Mer and Flt3 
proteins. Anti-Mer antibody or anti-Flt3 and rec-Protein 
G-sepharose beads (Invitrogen) were added and lysates 
were incubated overnight on a rocking platform. Beads 
were washed and eluted proteins were resolved as above. 
Immunoprecipitate membranes were probed with an 
anti-phospho-Mer or anti-phospho-Flt3 antibody. After 
visualization, membranes were stripped and reprobed 
for total protein. The following antibodies were used 
according to manufacturer recommendations: anti-Mer 
(ab52968, AbCam); anti-phospho-Mer (Phosphosolutions 
Inc.) [34, 39]; anti-Flt3 (sc-480), anti-Actin (sc-1616), 
anti-pan-Trk (sc-11), donkey-anti-goat IgG-HRP (sc-
2020) (Santa Cruz Biotechnology); anti-phospho-Flt3 
(#3461), anti-phospho-Stat6 (Tyr641, #9364), anti-Stat6, 
(#9362), anti-phospho-Stat5 (Tyr694, #9359), anti-Stat5 
(#9358), anti-phospho-AKT (Ser473, #9271L), anti-AKT 
(#9272), anti-phospho-p44/42-MAPK (ERK1/2, Thr202/
Tyr204, #9106), anti-p44/42-MAPK (#9102), anti-PARP 
(#9542), anti-Caspase-3 (#9665), anti-Tyro-3 (#5585) 
(Cell Signaling Technology); anti-Axl (AF154, R&D 
Systems); goat-anti-mouse IgG-HRP, goat-anti-rabbit IgG-
HRP (BioRad). Proteins were visualized by horseradish 
peroxidase chemiluminescence detection (Perkin-Elmer).
Apoptosis & replating assays
To assess apoptosis, AML cell lines were cultured 
at 3 × 105 cells, and 1 × 106 AML patient blasts were co-
cultured with 3.5 × 105 HS27 cells per condition in 24 
well plates, and treated for 72 hours. Harvested cells 
were washed, resuspended in PBS containing 1 μM 
YO-PRO®-1 iodide (Invitrogen) and 1.5 μM propidium 
iodide (PI) (Invitrogen), and incubated on ice for 15–20 
minutes. Fluorescence was detected and analyzed using 
a FC500 flow cytometer with CXP data analysis software 
(Beckman Coulter). For cell cycle analyses, cells were 
fixed with 100% ethanol after treatment for 72 hours with 
UNC1666 or controls, stained with PI overnight, and 
analyzed on a Gallios flow cytometer. Flow cytometry 
data were analyzed using Modfit Cell Cycle Analysis 
software (Verity Software House). In replating assays, 
cells were similarly plated and treated, then harvested cells 
were washed twice, and 1.5 × 104 viable cells/ml were 
cultured in cRPMI for six days. Six days after replating, 
viable myeloblast count was determined by trypan blue 
exclusion using a Cedex XS Analyzer (Roche).
Colony formation assays
Cell lines were plated at a density of 1000 cells/
ml in 0.35% agar over 0.5% agar base layer. Agar was 
overlaid with cRPMI containing UNC1666, UNC1653, or 
vehicle. Colonies were grown for 14 (NOMO-1, MV4;11, 
MOLM-13) or 21 days (Kasumi-1) prior to staining 
with 1 mg/ml nitrotetrazolium blue (Sigma-Aldrich). 
Treatment-containing medium was renewed twice weekly. 
Patient samples were plated at a density of 1 × 106 cells/
ml in MethoCult H4434 Classic Methylcellulose-Based 
Medium with Recombinant Cytokines for Human Cells 
(StemCell Technologies) containing UNC1666 or vehicle 
in triplicate and colonies were grown for 10 days. Human 
mononuclear cells were isolated from umbilical cord 
blood samples using Ficoll-Paque PLUS (GE Healthcare 
Life Sciences). Cells were grown in serum-free IMDM 
(HyClone) media containing BIT 9500 Serum Substitute 
(StemCell Technologies), lipoprotein lipase (Millipore), 
and 2-mercaptoethanol (Sigma) for one hour, then plated 
in Methocult H4434 methylcellulose containing UNC1666 
or vehicle at 2 × 106 cells/mL in triplicate and colonies 
were grown for 14 days. Cell line and patient sample 
colonies were counted using a GelCount colony counter 
(Oxford Optronix) and cord blood colonies were manually 
counted in a blinded, non-biased manner.
Statistical analysis
Statistical analyses were performed using GraphPad 
Prism software (v6.02), comparing UNC1666 and vehicle-
treated samples. Cell cycle and replating assays were 
analyzed using two-way ANOVA. All other data were 
analyzed using one-way ANOVA. All statistics were 
corrected using Bonferroni’s multiple comparisons test. 
Results were considered significant when p < 0.05.
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